- Home
- TNFA vs KZIA Comparison
TNFA vs KZIA Comparison
Compare TNFA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNFA
- KZIA
- Stock Information
- Founded
- TNFA 2014
- KZIA 1994
- Country
- TNFA United States
- KZIA Australia
- Employees
- TNFA N/A
- KZIA N/A
- Industry
- TNFA
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- TNFA
- KZIA Health Care
- Exchange
- TNFA NYSE
- KZIA Nasdaq
- Market Cap
- TNFA 760.1K
- KZIA 860.8K
- IPO Year
- TNFA N/A
- KZIA 1999
- Fundamental
- Price
- TNFA $0.22
- KZIA $3.64
- Analyst Decision
- TNFA
- KZIA Strong Buy
- Analyst Count
- TNFA 0
- KZIA 2
- Target Price
- TNFA N/A
- KZIA $57.50
- AVG Volume (30 Days)
- TNFA 2.7M
- KZIA 30.1K
- Earning Date
- TNFA 04-11-2025
- KZIA 05-02-2025
- Dividend Yield
- TNFA N/A
- KZIA N/A
- EPS Growth
- TNFA N/A
- KZIA N/A
- EPS
- TNFA N/A
- KZIA N/A
- Revenue
- TNFA N/A
- KZIA $1,655,324.00
- Revenue This Year
- TNFA N/A
- KZIA N/A
- Revenue Next Year
- TNFA N/A
- KZIA N/A
- P/E Ratio
- TNFA N/A
- KZIA N/A
- Revenue Growth
- TNFA N/A
- KZIA 248000.00
- 52 Week Low
- TNFA $0.16
- KZIA $2.86
- 52 Week High
- TNFA $3.37
- KZIA $79.00
- Technical
- Relative Strength Index (RSI)
- TNFA 35.77
- KZIA 44.45
- Support Level
- TNFA $0.18
- KZIA $2.86
- Resistance Level
- TNFA $0.20
- KZIA $3.77
- Average True Range (ATR)
- TNFA 0.04
- KZIA 0.50
- MACD
- TNFA -0.00
- KZIA 0.05
- Stochastic Oscillator
- TNFA 27.88
- KZIA 60.00
About TNFA TNF PHARMACEUTICALS INC EFFEC
TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.